Skip to main content

Advertisement

SpringerLink
Log in

Cyclophosphamide and Lupus Nephritis: When, How, For How Long?

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Ever since the introduction of cyclophosphamide (CY), the management of lupus nephritis has dramatically changed, and its prognosis has greatly improved. Based on randomized controlled trials and long-term observational studies, pulse therapy with CY in combination with methyl-prednisolone (MP) is the “gold standard” of therapy for severe lupus. The realization of the significant gonadal toxicity intensified the efforts for the development of alternative immunosuppressive agents. In a large, randomized controlled trial, newer agents such as mycophenolate mofetil (MMF) have demonstrated comparable efficacy and less toxicity for moderately severe disease. To date, combinations of monthly pulses of CY with MP remain the gold standard for the induction of remission in severe lupus. For maintenance, less toxic agents such as azathioprine or MMF are equally effective and are routinely used in the current therapy of lupus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Struck RF, Alberts DS, Horne K, Phillips JG, Peng YM, Roe DJ (1987) Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res 47:2723–2726

    PubMed  CAS  Google Scholar 

  2. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D (2002) Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 61:1495–1501

    Article  PubMed  CAS  Google Scholar 

  3. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM (1978) Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299:1151–1155

    Article  PubMed  Google Scholar 

  4. Austin HA 3rd, Klippel JH, Balow JE et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619

    Article  PubMed  Google Scholar 

  5. Boumpas DT, Austin HA 3rd, Vaughn EM et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745

    Article  PubMed  CAS  Google Scholar 

  6. Gourley MF, Austin HA 3rd, Scott D et al (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125:549–557

    PubMed  CAS  Google Scholar 

  7. Illei GG, Austin HA, Crane M et al (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248–257

    PubMed  CAS  Google Scholar 

  8. Houssiau FA, Vasconcelos C, D’Cruz D et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131

    Article  PubMed  CAS  Google Scholar 

  9. Houssiau FA, Vasconcelos C, D’Cruz D et al (2010) The 10-year follow-up data of the euro-lupus nephritis trial comparing low-dose versus high-dose intravenous cyclophosphamide. Ann Rheum Dis 69:61–64

    Google Scholar 

  10. Chan TM, Li FK, Hao WK et al (1999) Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 8:545–551

    Article  PubMed  CAS  Google Scholar 

  11. Austin HA, Illei GG, Braun MJ, Balow JE (2009) Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20:901–911

    Article  PubMed  CAS  Google Scholar 

  12. Mok CC, Ying KY, Ng WL et al (2006) Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119(355):e25–e33

    PubMed  Google Scholar 

  13. de Groot K, Harper L, Jayne DR et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670–680

    PubMed  Google Scholar 

  14. Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156–1162

    Article  PubMed  CAS  Google Scholar 

  15. Chan TM, Tse KC, Tang CS, Mok MY, Li FK (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16:1076–1084

    Article  PubMed  CAS  Google Scholar 

  16. Contreras G, Pardo V, Leclercq B et al (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980

    Article  PubMed  CAS  Google Scholar 

  17. Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228

    Article  PubMed  CAS  Google Scholar 

  18. Ong LM, Hooi LS, Lim TO et al (2005) Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 10:504–510

    Article  CAS  Google Scholar 

  19. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS (2009) Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 48:944–952

    Article  CAS  Google Scholar 

  20. Grootscholten C, Ligtenberg G, Hagen EC et al (2006) Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 70:732–742

    Article  PubMed  CAS  Google Scholar 

  21. Grootscholten C, Bajema IM, Florquin S et al (2007) Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 56:924–937

    Article  PubMed  CAS  Google Scholar 

  22. Bosch X, Guilabert A, Pallares L et al (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15:584–589

    Article  PubMed  CAS  Google Scholar 

  23. Pryor BD, Bologna SG, Kahl LE (1996) Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39:1475–1482

    Article  PubMed  CAS  Google Scholar 

  24. Ramos-Casals M, Cuadrado MJ, Alba P et al (2008) Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine (Baltimore) 87:311–318

    Article  Google Scholar 

  25. Mosca M, Tani C, Aringer M et al (2009) EULAR Recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies. Ann Rheum Dis (in press)

  26. Bernatsky S, Clarke AE, Ramsey-Goldman R (2008) Cancer in systemic lupus: what drives the risk? Cancer Causes Control 19:1413–1414

    Article  PubMed  Google Scholar 

  27. Turnbull J, Harper L (2009) Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 23:391–401

    Article  PubMed  Google Scholar 

  28. Ognenovski VM, Marder W, Somers EC et al (2004) Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 31:1763–1767

    PubMed  CAS  Google Scholar 

  29. Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366–369

    PubMed  CAS  Google Scholar 

  30. Rivkees SA, Crawford JD (1988) The relationship of gonadal activity and chemotherapy-induced gonadal damage. Jama 259:2123–2125

    Article  PubMed  CAS  Google Scholar 

  31. Raptopoulou A, Sidiropoulos P, Boumpas D (2004) Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus. Lupus 13:887–890

    Article  PubMed  Google Scholar 

  32. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M (2000) Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 9:401–405

    Article  PubMed  CAS  Google Scholar 

  33. von Scheven E, Bakkaloglu A (2009) What’s new in paediatric SLE? Best Pract Res Clin Rheumatol 23:699–708

    Article  Google Scholar 

  34. Lehman TJ, Sherry DD, Wagner-Weiner L et al (1989) Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 114:1055–1060

    Article  PubMed  CAS  Google Scholar 

  35. Lehman TJ, Onel K (2000) Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 136:243–247

    Article  PubMed  CAS  Google Scholar 

  36. Lau KK, Ault BH, Jones DP, Butani L (2008) Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. J Pediatr Health Care 22:282–288

    Article  PubMed  Google Scholar 

  37. Askenazi D, Myones B, Kamdar A et al (2007) Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy. Pediatr Nephrol 22:981–986

    Article  PubMed  Google Scholar 

  38. Demircin G, Oner A, Erdogan O et al (2008) Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis. Ren Fail 30:603–609

    Article  PubMed  CAS  Google Scholar 

  39. Benseler SM, Bargman JM, Feldman BM et al (2009) Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome. Rheumatology (Oxford) 48:176–182

    Article  CAS  Google Scholar 

  40. Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58:556–562

    Article  PubMed  Google Scholar 

  41. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS (2008) Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19:2001–2010

    Article  PubMed  CAS  Google Scholar 

  42. Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Clinical Immunology, and Allergy, University of Crete Medical School, Voutes, P. O. Box 2209, Heraklion, Greece

    Stella Ntali & Dimitrios T. Boumpas

  2. Department of Internal Medicine, University of Crete School of Medicine, Voutes, P. O. Box 2209, Heraklion, Greece

    George Bertsias & Dimitrios T. Boumpas

Authors
  1. Stella Ntali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Bertsias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimitrios T. Boumpas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimitrios T. Boumpas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ntali, S., Bertsias, G. & Boumpas, D.T. Cyclophosphamide and Lupus Nephritis: When, How, For How Long?. Clinic Rev Allerg Immunol 40, 181–191 (2011). https://doi.org/10.1007/s12016-009-8196-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-009-8196-0

Keywords

Search

Navigation